Currently, there are six clinical trials available for treatment-naïve AIDS/HIV patients: ACTG A5001, Acute HIV Longitudinal Trial, CHAVI 001, CHAVI 012, CHAVI B-cell, Proteinuria, and the True Prevalance Study. All are currently open for enrollment, though the individual requirements and treatments for each study differ.
The purpose of this observational study is to provide long-term follow up of acutely/recently HIV infected patients.
Requirements for this study include:
Treatment will include:
To become involved, contact Kara McGee:
Chavi 001 is an acute HIV-1 infection prospective cohort study to acquire data for HIV vaccine development.
Requirements for this study include:
Treatment will include:
To become involved, contact Kara McGee:
Acute infection observation study. One visit with possible follow-up.
Requirements for this study include:
Possible procedures compensated by study:
To become involved, contact Kara McGee:
The Chavi B-cell study intends to assess the immune systems of chronically infected patients to inform development of an HIV vaccine.
Requirements for this study include:
Treatment will include:
To become involved, contact Kara McGee:
The purpose of this observational study is to assess endothelial cell function in HIV infected patients with and without proteinuria.
Requirements for this study include:
Treatment will include:
To become involved, contact Joan Riddle, RN:
Use of current or new genotype testing to detect low level resistance, particularly to NNRTIs that may cause treatment failure or emergence of further resistance.
Requirements for this study include:
This is an observational study.
To become involved, contact Brian Lane, RN, or Lynn McNeil, RN: